Скачать или смотреть ESR1 Mutations in Focus: Are PROTACs the Next Breakthrough?

This video explains the VERITAC-2 trial, focused on a new pill that induces cancer cells to dismantle their own growth mechanisms, representing an exciting area of cancer research. The video further elaborates on how PROTAC drugs function specifically in hormone receptor positive breast cancer, offering a glimpse into the potential of targeted protein degradation. This innovative approach shows promising results in medical research.

Explore the key findings from the Veritac-2 trial, presented at the #ASC025 Annual Meeting (⁨@ASCOcancer⁩), highlighting significant benefits for patients with ESR1 mutations, including improved progression-free survival. The video also covers the drug's safety profile and its potential to change treatment strategies for resistant breast cancer, emphasizing the importance of genomic testing.

#breastcancerawareness #CancerTreatment #PROTAC #Veritac2 #Vepdegestrant #ESR1Mutation #HormonePositiveBreastCancer #ClinicalTrial #Oncology #NewDrug #asco25 #fda

CHAPTERS
00:00 Introduction
00:08 Veritac-2 Study Overview: PROTACs for Breast Cancer
00:16 Hormone-Positive Breast Cancer & Treatment Challenges
00:41 The Veritac-2 Trial: Vepdegestrant vs. Fulvestrant
01:00 Patient Focus: Advanced Cancer & ESR1 Mutations
01:20 Vepdegestrant & The PROTAC Mechanism of Action
02:31 Key Findings: Efficacy in ESR1 Mutant & Overall Groups
03:19 Safety and Tolerability of Vepdegestrant
03:39 Clinical Implications & Future Directions

About Dr. Esteva
Francisco J. Esteva, MD, PhD is a medical oncologist based in New York with a specialization in breast cancer. He completed an Oncology Fellowship at Georgetown University Hospital and an Internal Medicine Residency at Cooper Medical School of Rowan University. Dr. Esteva serves as Division Chief at Lenox Hill Hospital and has previously held faculty appointments at NYU and The University of Texas MD Anderson Cancer Center. He has authored numerous peer-reviewed publications and has led more than 100 clinical trials focused on breast cancer treatment, diagnostics, and predictive biomarkers. His honors include Fellowship in the American College of Physicians, election to the American Society for Clinical Investigation, the 2019 Physician of Impact Award from Susan G. Komen NYC, and election to the NYC American Cancer Society Board of Advisors in 2024.

Medical Disclaimer
The content in this video is intended for informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek guidance from your physician or another qualified health professional regarding any medical condition. Do not disregard professional medical advice or delay seeking care because of information presented in this video. The views shared in this video represent Dr. Esteva’s personal opinions and do not reflect those of his employer.

Non-Sponsorship & Affiliation Disclaimer
This video is not sponsored. Any mention of products, medications, or brands is for educational purposes only and does not imply endorsement. Advertisements that may appear are placed by YouTube; I am not affiliated with, nor do I endorse, any advertised products or services.